Adimab Stock
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Sign up today and learn more about Adimab Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Adimab Stock
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Funding History
July 2007 | $6.2M |
---|---|
July 2007 | $2K |
September 2007 | $5.9M |
March 2008 | $3.2M |
November 2008 | $4.0M |
January 2010 | $8.2M |
December 2010 | $4.0M |
April 2012 | $14.0M |
Management
General Counsel
Philip Chase
Advisor
Colin Greenspon
VP, Head, Business Development
Guy Van Meter
Co-founder, Chair of the SAB
K. Dane Wittrup
Board Member
Tillman Gerngross
Founder, CEO
Tillman Gerngross
Board of Directors
Carl L. Gordon
Member of the Board of Directors
Bill Maris
VP Computational Biology
Max Vasquez
Chief Scientific Officer
Eric Krauland
Director, Open Innovation
Piotr Bobrowicz
Co-Founder
Errik Anderson
Member of the Board of Directors
Terrance McGuire
Press
endpts - Jan, 14 2024
LinkedUp, TianTi end legal dispute with Adimab over yeast-based antibody platformbiospace - Jan, 12 2024
Adimab Provides 2023 Update on Clinical Pipelinebiospace - Feb, 10 2023
Ablexis Announces License Agreement with Adimabfiercebiotech - May, 12 2022
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 yearsbiospace - May, 11 2022
ADC, Adimab and Longeveron Begin New Leadership Chapters